The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Frutarom

Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition

Concordia International Corp.

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

Novartis AG’s 36.5% stake in Consumer Health Joint Venture

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

Grupo Rudelman

Advised Inchcape PLC, a global leader in automotive and distribution, on the acquisition of Grupo Rudelman, a Suzuki-focused distribution business in Costa Rica and Panama

Hirslanden Private Hospital Group

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

Mãe Terra Produtos Naturais Ltda.

Advised Mãe Terra Produtos Naturais Ltda., Brazil’s leading Natural & Organic food products company, on its sale to The Unilever Group

L.L.Bean (Credit Card Assets)

Advised L.L.Bean Inc. on a strategic alliance relating to its credit card business with Citibank, N.A.

Equity stake in Bupa Arabia

Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia

Booker Group plc

Advised Tesco plc, the UK’s leading retailer, on its merger with Booker Group plc, the UK’s leading food wholesaler, to create the UK’s leading food business

Derma Sciences, Inc.

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on its sale to Integra LifeSciences Holdings Corporation, a global leader in medical technology

Palatin Technologies, Inc. lead product candidate, Rekynda

Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.

Subsidiaries and affiliates of Empresas Indumotora S.A.

Advised Inchcape PLC, a global leader in automotive retail and distribution, on the acquisition of a multi-country scale distribution business in Chile, Peru, Colombia, and Argentina for $290m (approximately £234m)

Peacock Foods

Advised Greencore Group plc, a leading international manufacturer of convenience foods based in Ireland, on the proposed acquisition of Peacock Foods, a manufacturing partner for consumer packaged goods companies in the US.

Fragrance Resources Group

Advised IFF, one of the world’s largest flavors and fragrances businesses, on the acquisition of Fragrance Resources Group, a family-owned fragrance company headquartered in Switzerland

Save-A-Lot

Advised SUPERVALU, Inc., one of the largest grocery wholesalers and retailers in the US, on the sale of its Save-A-Lot business, a leading hard-discount grocery retailer in the U.S., to an affiliate of Onex Corporation

Concordia International Corp

Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

US rights to Toprol-XL (AstraZeneca)

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

BioD, LLC

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.

US rights to an authorized generic version of Adderall XR

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR

US rights to 37 approved and 5 pipeline generic products

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila

Dobbies Garden Centres

Advised Tesco plc, a listed FTSE 100 retailer, on its sale of Dobbies Garden Centres to an investor group led by Midlothian Capital Partners and Hattington Capital